View of Sequential Gemcitabine and Docetaxel Versus BCG for High-Risk Non-Muscle-Invasive Bladder Cancer

Return to Article Details Sequential Gemcitabine and Docetaxel Versus BCG for High-Risk Non-Muscle-Invasive Bladder Cancer Download Download PDF